TheraSphere Selective Internal Radiation Therapy (SIRT) as Treatment for Neuroendocrine Tumours With Liver Mets

Inclusion Criteria: All patients must be discussed at a specialist hepatobiliary multi-disciplinary team meeting (MDT) and meet the following criteria: * Histologically confirmed neuroendocrine tumour, with documented grade. * \>18 years of age * Patients may be on SSAs concurrently.Patients must have had at least one previous line of therapy * Unresectable liver only or liver predominant metastases (typically involving \>25% but \<60% of the liver, and technically inoperable, or unfeasible secondary to medical comorbidity) * Have measurable disease by RECIST 1.1 criteria * Life expectancy of \>12 weeks * Eastern Cooperative Oncology Group (ECOG) / World Health Organisation (WHO) Performance Status of 0-1 * Adequate liver function (bilirubin less than 34 umol/L in the absence of a reversible cause) * Blood work: patients must have * Platelet count of \> or = to 50x10\^9/L * Hb of \> or = to 8.5g/dL * Alanine Aminotransferase (ALT) and Aspartate transaminase (AST) \< 5 x Upper limit of normal (ULN) * Serum creatinine \< 1.5 x ULN * Internal Normalised Ration (INR) \< 2.0 * Patients with portal vein thrombosis may be considered, as determined at MDT (A compromised main portal vein as demonstrated on triple-phase CT scan unless selective or super-selective SIRT can be performed and the other safety criteria are fulfilled) Exclusion Criteria: Patients who meet any of the following exclusion criteria will NOT be considered eligible for this study. * Clinically appa…